Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation

References

• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–1669. doi: 10.1053/j.gastro.2008.03.003
   PubMed Web of Science ®Google Scholar
• Schuppan D. Liver fibrosis: common mechanisms and antifibrotic therapies. Clin Res Hepatol Gastroenterol. 2015;39(Suppl 1):S51–59. doi: 10.1016/j.clinre.2015.05.005
   PubMedGoogle Scholar
• Trautwein C, Friedman SL, Schuppan D, et al. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1):S15–24. doi: 10.1016/j.jhep.2015.02.039
   PubMedGoogle Scholar
• Lin Y, Mehta S, Küçük-McGinty H, et al. Drug target ontology to classify and integrate drug discovery data. J Biomed Semantics. 2017;8(1):50. doi: 10.1186/s13326-017-0161-x
   PubMedGoogle Scholar
• Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4(1):62. doi: 10.1038/s41392-019-0095-0
   PubMedGoogle Scholar
• Gelato KA, Adler D, Ocker M, et al. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRnas. Expert Opin Ther Targets. 2016;20(7):783–799. doi: 10.1517/14728222.2016.1134490
   PubMed Web of Science ®Google Scholar
• Roux PP, Topisirovic I. Signaling pathways involved in the regulation of mRNA translation. Mol Cell Biol. 2018;38(12):e00070–18. doi: 10.1128/MCB.00070-18
   PubMed Web of Science ®Google Scholar
• Ramazi S, Zahiri J. Posttranslational modifications in proteins: resources, tools and prediction methods. Database (Oxford). 2021;2021:baab012. doi: 10.1093/database/baab012
   PubMedGoogle Scholar
• Yang Y-H, Wen R, Yang N, et al. Roles of protein post-translational modifications in glucose and lipid metabolism: mechanisms and perspectives. Mol Med. 2023;29(1):93. doi: 10.1186/s10020-023-00684-9
   PubMed Web of Science ®Google Scholar
• Laham-Karam N, Pinto GP, Poso A, et al. Transcription and translation inhibitors in cancer treatment. Front Chem. 2020;8:276. doi: 10.3389/fchem.2020.00276
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, HHS. International Conference on Harmonisation. Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice. Fed Regist. 2010Mar 8;75( 44):10487–10488. PMID: 20383918.
   Google Scholar
• Wu C, Cheng D, Peng Y, et al. Hepatic BRD4 is upregulated in liver fibrosis of various etiologies and positively correlated to fibrotic severity. Front Med. 2021;8:683506. doi: 10.3389/fmed.2021.683506
   Web of Science ®Google Scholar
• Ding N, Hah N, Yu RT, et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci U S A. 2015;112(51):15713–15718. doi: 10.1073/pnas.1522163112
   PubMed Web of Science ®Google Scholar
• Fu R, Zu S-J, Liu Y-J, et al. Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis. Bioengineered. 2022;13(4):10914–10930. doi: 10.1080/21655979.2022.2066756
   PubMed Web of Science ®Google Scholar
• Middleton SA, Rajpal N, Cutler L, et al. BET inhibition Improves NASH and liver fibrosis. Sci Rep. 2018;8(1):17257. doi: 10.1038/s41598-018-35653-4
   PubMedGoogle Scholar
• Kang J-H, Splinter PL, Trussoni CE, et al. The epigenetic Reader, bromodomain containing 2, mediates cholangiocyte senescence via interaction with ETS proto-oncogene 1. Gastroenterology. 2023;165(1):228–243.e2. doi: 10.1053/j.gastro.2023.03.235
   PubMed Web of Science ®Google Scholar
• Ettl T, Schulz D, Bauer R. The renaissance of cyclin dependent kinase inhibitors. Cancers. 2022;14(2):293. doi: 10.3390/cancers14020293
   PubMed Web of Science ®Google Scholar
• Shiekhattar R, Mermelstein F, Fisher RP, et al. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature. 1995;374(6519):283–287. doi: 10.1038/374283a0
   PubMed Web of Science ®Google Scholar
• Nemet J, Jelicic B, Rubelj I, et al. The two faces of Cdk8, a positive/negative regulator of transcription. Biochimie. 2014;97:22–27. doi: 10.1016/j.biochi.2013.10.004
   PubMed Web of Science ®Google Scholar
• Tsai K-L, Sato S, Tomomori-Sato C, et al. A conserved mediator–CDK8 kinase module association regulates mediator–RNA polymerase II interaction. Nat Struct Mol Biol. 2013;20(5):611–619. doi: 10.1038/nsmb.2549
   PubMed Web of Science ®Google Scholar
• Peng J, Zhu Y, Milton JT, et al. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 1998;12(5):755–762. doi: 10.1101/gad.12.5.755
   PubMed Web of Science ®Google Scholar
• Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616–620. doi: 10.1038/nature13393
   PubMed Web of Science ®Google Scholar
• Marineau JJ, Hamman KB, Hu S, et al. Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7. J Med Chem. 2022;65(2):1458–1480. doi: 10.1021/acs.jmedchem.1c01171
   PubMed Web of Science ®Google Scholar
• Garralda E, Schram AM, Bedard PL, et al. A Phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. Oncology. 2023;oyad215. doi: 10.1093/oncolo/oyad215
   Google Scholar
• Hatcher JM, Vatsan PS, Wang E, et al. Development of highly potent and selective pyrazolopyridine inhibitor of CDK8/19. ACS Med Chem Lett. 2021;12(11):1689–1693. doi: 10.1021/acsmedchemlett.1c00300
   PubMed Web of Science ®Google Scholar
• Chen C, Huang C, Xu M, et al. Abstract 5982: A potent and selective CDK8 inhibitor ABM-3249 with excellent efficacies in multiple in vivo cancer models. Cancer Res. 2023;83(7_Supplement):5982. doi: 10.1158/1538-7445.AM2023-5982
   Google Scholar
• Hofmann MH, Mani R, Engelhardt H, et al. Selective and potent CDK8/19 inhibitors enhance NK-Cell activity and promote tumor surveillance. Mol Cancer Ther. 2020;19(4):1018–1030. doi: 10.1158/1535-7163.MCT-19-0789
   PubMed Web of Science ®Google Scholar
• He X-L, Hu Y-H, Chen J-M, et al. SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9. Front Pharmacol. 2022;13:1016552. doi: 10.3389/fphar.2022.1016552
   PubMed Web of Science ®Google Scholar
• Cui D, Xu D, Yue S, et al. Recent advances in the pharmacological applications and liver toxicity of triptolide. Chem Biol Interact. 2023;382:110651. doi: 10.1016/j.cbi.2023.110651
   PubMed Web of Science ®Google Scholar
• Titov DV, Gilman B, He Q-L, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol. 2011;7(3):182–188. doi: 10.1038/nchembio.522
   PubMed Web of Science ®Google Scholar
• Manzo SG, Zhou Z-L, Wang Y-Q, et al. Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Res. 2012;72(20):5363–5373. doi: 10.1158/0008-5472.CAN-12-1006
   PubMed Web of Science ®Google Scholar
• Vispé S, DeVries L, Créancier L, et al. Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther. 2009;8(10):2780–2790. doi: 10.1158/1535-7163.MCT-09-0549
   PubMed Web of Science ®Google Scholar
• Chong L-W, Hsu Y-C, Chiu Y-T, et al. Antifibrotic effects of triptolide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. Phytother Res. 2011;25(7):990–999. doi: 10.1002/ptr.3381
   PubMed Web of Science ®Google Scholar
• Huang R, Guo F, Li Y, et al. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis. Phytomedicine. 2021;92:153739. doi: 10.1016/j.phymed.2021.153739
   PubMed Web of Science ®Google Scholar
• Yuan Z, Wang J, Zhang H, et al. Triptolide increases resistance to bile duct ligation-induced liver injury and fibrosis in mice by inhibiting RELB. Front Nutr. 2022;9:1032722. doi: 10.3389/fnut.2022.1032722
   PubMed Web of Science ®Google Scholar
• Laursen TL, Siggaard CB, Kazankov K, et al. Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat. 2020;27(1):28–35. doi: 10.1111/jvh.13204
   PubMed Web of Science ®Google Scholar
• Jackson RJ, Hellen CUT, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010;11(2):113–127. doi: 10.1038/nrm2838
   PubMed Web of Science ®Google Scholar
• Aitken CE, Lorsch JR. A mechanistic overview of translation initiation in eukaryotes. Nat Struct Mol Biol. 2012;19(6):568–576. doi: 10.1038/nsmb.2303
   PubMed Web of Science ®Google Scholar
• Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIf2α dephosphorylation protects cells from ER stress. Science. 2005;307(5711):935–939. doi: 10.1126/science.1101902
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Liu D, et al. Phosphorylation of eIf2α signaling pathway attenuates obesity-induced non-alcoholic fatty liver disease in an ER stress and autophagy-dependent manner. Cell Death Dis. 2020;11(12):1069. doi: 10.1038/s41419-020-03264-5
   PubMed Web of Science ®Google Scholar
• Zarei M, Pujol E, Quesada-López T, et al. Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. Br J Pharmacol. 2019;176(13):2292–2305. doi: 10.1111/bph.14678
   PubMed Web of Science ®Google Scholar
• Tan M, Pujol E, Vazquez S, et al. Abstract 638: EPB-53 prevents NASH-HCC transition via regulation of SPHK1-S1P-HIPPO signaling and immune modulation in a murine model. Cancer Res. 2023;83(7_Supplement):638. doi: 10.1158/1538-7445.AM2023-638
   Web of Science ®Google Scholar
• Tang X, Xie X, Wang X, et al. The combination of piR-823 and eukaryotic initiation factor 3 B (EIF3B) activates hepatic stellate cells via upregulating TGF-β1 in liver fibrogenesis. Med Sci Monit. 2018;24:9151–9165. doi: 10.12659/MSM.914222
   PubMed Web of Science ®Google Scholar
• He P, Yu Z-J, Sun C-Y, et al. Knockdown of eIf3a attenuates the pro-fibrogenic response of hepatic stellate cells induced by TGF-β1. Cell Mol Biol (Noisy-le-Grand). 2016;62(6):107–111.
   PubMed Web of Science ®Google Scholar
• Gufler S, Seeboeck R, Schatz C, et al. The translational bridge between inflammation and Hepatocarcinogenesis. Cells. 2022;11(3):533. doi: 10.3390/cells11030533
   PubMed Web of Science ®Google Scholar
• Villamil FG, Gadano AC, Zingale F, et al. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors. Liver Int. 2014;34(10):1513–1521. doi: 10.1111/liv.12416
   PubMed Web of Science ®Google Scholar
• Lu K, Fan Q, Zou X. Antisense oligonucleotide is a promising intervention for liver diseases. Front Pharmacol. 2022;13:1061842. doi: 10.3389/fphar.2022.1061842
   PubMed Web of Science ®Google Scholar
• Debacker AJ, Voutila J, Catley M, et al. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28(8):1759–1771. doi: 10.1016/j.ymthe.2020.06.015
   PubMed Web of Science ®Google Scholar
• Kim K-H, Park K-K. Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are? World J Gastroenterol. 2014;20(40):14696–14705. doi: 10.3748/wjg.v20.i40.14696
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366–1374. doi: 10.1002/hep.21655
   PubMed Web of Science ®Google Scholar
• Nuñez-Durán E, Aghajan M, Amrutkar M, et al. Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. Hepatol Commun. 2018;2(1):69–83. doi: 10.1002/hep4.1128
   PubMed Web of Science ®Google Scholar
• Nie Q-H, Zhu C-L, Zhang Y-F, et al. Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci. 2010;55(5):1286–1295. doi: 10.1007/s10620-009-0858-5
   PubMed Web of Science ®Google Scholar
• Nie QH, Cheng YQ, Xie YM, et al. Inhibiting effect of antisense oligonucleotides phosphorothioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol. 2001;7(3):363–369. doi: 10.3748/wjg.v7.i3.363
   PubMed Web of Science ®Google Scholar
• Horie S, Kitamura Y, Kawasaki H, et al. Inhibitory effects of antisense oligonucleotides on the expression of procollagen type III gene in mouse hepatic stellate cells transformed by simian virus 40. Pathol Int. 2000;50(12):937–944. doi: 10.1046/j.1440-1827.2000.01146.x
   PubMed Web of Science ®Google Scholar
• Liu W-B, Yang C-Q, Jiang W, et al. Inhibition on the production of collagen type I, III of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid. World J Gastroenterol. 2003;9(2):316–319. doi: 10.3748/wjg.v9.i2.316
   PubMed Web of Science ®Google Scholar
• Yu J, Zhu C, Wang X, et al. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Sci Transl Med. 2021;13(599):eabe1692. doi: 10.1126/scitranslmed.abe1692
   PubMed Web of Science ®Google Scholar
• Tang M, Chen Y, Li B, et al. Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis. FASEB J. 2021;35(5):e21557. doi: 10.1096/fj.202002777RR
   PubMed Web of Science ®Google Scholar
• Mello CC, Conte D. Revealing the world of RNA interference. Nature. 2004;431(7006):338–342. doi: 10.1038/nature02872
   PubMed Web of Science ®Google Scholar
• Hu P-F, Xie W-F. Targeted RNA interference for hepatic fibrosis. Expert Opin Biol Ther. 2009;9(10):1305–1312. doi: 10.1517/14712590903213677
   PubMed Web of Science ®Google Scholar
• Ito S, Nagata K. Roles of the endoplasmic reticulum–resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease. J Biol Chem. 2019;294(6):2133–2141. doi: 10.1074/jbc.TM118.002812
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Shevell DE, Tirucherai GS, et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022;75(4):912–923. doi: 10.1002/hep.32181
   PubMed Web of Science ®Google Scholar
• Strnad P, Mandorfer M, Choudhury G, et al. Fazirsiran for liver disease associated with Alpha1-antitrypsin deficiency. N Engl J Med. 2022;387(6):514–524. doi: 10.1056/NEJMoa2205416
   PubMed Web of Science ®Google Scholar
• Morita K, Taketomi A, Shirabe K, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int. 2011;31(4):474–484. doi: 10.1111/j.1478-3231.2010.02433.x
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198–201. doi: 10.1126/science.1178178
   PubMed Web of Science ®Google Scholar
• van der Ree MH, de Vree JM, Stelma F, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017;389(10070):709–717. doi: 10.1016/S0140-6736(16)31715-9
   PubMed Web of Science ®Google Scholar
• Stelma F, van der Ree MH, Sinnige MJ, et al. Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101. Hepatology. 2017;66(1):57–68. doi: 10.1002/hep.29148
   PubMed Web of Science ®Google Scholar
• Deng Y, Campbell F, Han K, et al. Randomized clinical trials towards a single-visit cure for chronic hepatitis C: oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. J Viral Hepat. 2020;27(7):699–708. doi: 10.1111/jvh.13282
   PubMed Web of Science ®Google Scholar
• Hamasaki T, Suzuki H, Shirohzu H, et al. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One. 2012;7(8):e42655. doi: 10.1371/journal.pone.0042655
   PubMed Web of Science ®Google Scholar
• Dalgaard LT, Sørensen AE, Hardikar AA, et al. The microRNA-29 family: role in metabolism and metabolic disease. Am J Physiol Cell Physiol. 2022;323(2):C367–C377. doi: 10.1152/ajpcell.00051.2022
   PubMed Web of Science ®Google Scholar
• Huang Y-H, Tiao M-M, Huang L-T, et al. Activation of mir-29a in activated hepatic stellate cells modulates its profibrogenic phenotype through inhibition of histone deacetylases 4. PLoS One. 2015;10(8):e0136453. doi: 10.1371/journal.pone.0136453
   PubMed Web of Science ®Google Scholar
• Liang C, Bu S, Fan X. Suppressive effect of microRNA-29b on hepatic stellate cell activation and its crosstalk with TGF-β1/Smad3. Cell Biochem Funct. 2016;34(5):326–333. doi: 10.1002/cbf.3193
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Kuo H-C, Wang F-S, et al. MicroRNA-29a disrupts DNMT3b to ameliorate diet-induced non-alcoholic steatohepatitis in mice. Int J Mol Sci. 2019;20(6):1499. doi: 10.3390/ijms20061499
   PubMed Web of Science ®Google Scholar
• Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020;72(6):1196–1209. doi: 10.1016/j.jhep.2020.02.020
   PubMed Web of Science ®Google Scholar
• Carlsson B, Lindén D, Brolén G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305–1320. doi: 10.1111/apt.15738
   PubMed Web of Science ®Google Scholar
• Chen Y, Du X, Kuppa A, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet. 2023;55(10):1640–1650. doi: 10.1038/s41588-023-01497-6
   PubMed Web of Science ®Google Scholar
• Helsley RN, Varadharajan V, Brown AL, et al. Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. Elife. 2019;8:e49882. doi: 10.7554/eLife.49882
   PubMed Web of Science ®Google Scholar
• Varadharajan V, Ramachandiran L, Massey WJ, et al. Membrane bound O-Acyltransferase 7 (MBOAT7) shapes lysosomal lipid homeostasis and function to control alcohol-associated liver injury. bioRxiv. 2023 Sep 26;559533. doi: 10.1101/2023.09.26.559533
   Google Scholar
• Fuchs CD, Radun R, Dixon ED, et al. Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice. Hepatology. 2022;75(1):125–139. doi: 10.1002/hep.32112
   PubMed Web of Science ®Google Scholar
• Schwartz BE, Rajagopal V, Smith C, et al. Discovery and targeting of the signaling controls of PNPLA3 to effectively reduce transcription, expression, and function in pre-clinical NAFLD/NASH settings. Cells. 2020;9(10):2247. doi: 10.3390/cells9102247
   PubMed Web of Science ®Google Scholar
• Liu S, Murakami E, Nakahara T, et al. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. Mol Med Rep. 2021;23(1):16. doi: 10.3892/mmr.2020.11654
   PubMed Web of Science ®Google Scholar
• Cherubini A, Casirati E, Tomasi M, et al. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets. 2021;25(12):1033–1043. doi: 10.1080/14728222.2021.2018418
   PubMed Web of Science ®Google Scholar
• Lindén D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab. 2019;22:49–61. doi: 10.1016/j.molmet.2019.01.013
   PubMed Web of Science ®Google Scholar
• Smith CR, Powell RG, Mikolajczak KL. The genus cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep. 1976;60(8):1157–1170.
   PubMedGoogle Scholar
• Fresno M, Jiménez A, Vázquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977;72(2):323–330. doi: 10.1111/j.1432-1033.1977.tb11256.x
   PubMedGoogle Scholar
• Tujebajeva RM, Graifer DM, Karpova GG, et al. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett. 1989;257(2):254–256. doi: 10.1016/0014-5793(89)81546-7
   PubMed Web of Science ®Google Scholar
• Alvandi F, Kwitkowski VE, Ko C-W, et al. U.S. Food and drug administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncology. 2014;19(1):94–99. doi: 10.1634/theoncologist.2013-0077
   Google Scholar
• Yang C, Zhang H, Chen M, et al. A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. Elife. 2022;11:e71880. doi: 10.7554/eLife.71880
   PubMed Web of Science ®Google Scholar
• Yerukala Sathipati S, Tsai M-J, Shukla SK, et al. Artificial intelligence-driven pan-cancer analysis reveals miRNA signatures for cancer stage prediction. HGG Adv. 2023;4(3):100190. doi: 10.1016/j.xhgg.2023.100190
   PubMedGoogle Scholar
• Sun J, Ru J, Ramos-Mucci L, et al. DeepsmirUD: prediction of regulatory effects on microRNA expression mediated by small molecules using deep learning. Int J Mol Sci. 2023;24(3):1878. doi: 10.3390/ijms24031878
   PubMed Web of Science ®Google Scholar
• Li J, Lin H, Wang Y, et al. Prediction of potential small molecule-miRNA associations based on heterogeneous network representation learning. Front Genet. 2022;13:1079053. doi: 10.3389/fgene.2022.1079053
   PubMed Web of Science ®Google Scholar